• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by Matinas Biopharma Holdings Inc.

    7/16/26 5:27:14 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTNB alert in real time by email
    425 1 form425.htm 425

     

    Filed by Matinas BioPharma Holdings, Inc.

    pursuant to Rule 425 under the Securities Act of 1933

    and deemed filed pursuant to Rule 14a-12

    under the Securities Exchange Act of 1934

    Subject Company: Matinas BioPharma Holdings, Inc.

    Commission File No. 001-38022

    Date: July 16, 2026

     

    As previously disclosed, on July 10, 2026, Matinas BioPharma Holdings, Inc. (the “Company”), GH Power Inc., a corporation organized under the laws of Ontario (“GH Power”), 1001550000 Ontario Inc., a corporation organized under the laws of Ontario (“Pubco”), 1001550002 Ontario Inc., a corporation organized under the laws of Ontario and a wholly owned subsidiary of Pubco (“GH Power Merger Sub”), and MBH Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Pubco (“Matinas Merger Sub”), entered into a Business Combination Agreement.

     

    The following communication was sent by GH Power to its shareholders on July 16, 2026.

     

    Subject: GH Power and Matinas BioPharma Enter Definitive Business Combination Agreement

     

    Dear Shareholders:

     

    GH Power has entered into a definitive business combination agreement with Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas”). If the proposed transaction is completed, GH Power and Matinas will become wholly owned subsidiaries of a newly formed Ontario corporation expected to be named GH Power International (“GHP International”). Following completion of the transaction, it is expected that GHP International’s common shares will be listed on the NYSE American, subject to approval of the listing application and satisfaction of the exchange’s applicable listing standards.

     

    Based on the current transaction terms, existing GH Power shareholders are expected to own approximately 91% of GHP International’s outstanding equity at closing, and existing Matinas stockholders are expected to own approximately 9%. However, these percentages are subject to adjustment under the business combination agreement and plan of arrangement, including for capital raised by GH Power or Matinas before closing and for certain other issuances.

     

    We believe the proposed transaction would provide GH Power with a public-company platform and access to the public capital markets to support commercialization of its proprietary modular reactor technology, which is designed to transform scrap metals and water into green hydrogen, high-purity alumina, and usable heat. Completion of the transaction is subject to shareholder, regulatory, court, financing, and exchange approvals and other closing conditions described below.

     

    Transaction Structure

     

    The transaction contemplated by the business combination agreement uses a holding-company structure. At closing, GH Power and Matinas would each become a wholly owned subsidiary of GHP International, and GH Power shareholders and Matinas stockholders would receive GHP International common shares in accordance with the business combination agreement and plan of arrangement.

     

    Compared with a traditional initial public offering, GH Power believes a business combination of this type may offer a more efficient path to the public markets, including a potentially shorter timeline to listing, reduced offering and underwriting costs, and access to an established public-company reporting and exchange-listing infrastructure. There can be no assurance, however, that these anticipated benefits will be realized.

     

     
     

     

    PIPE Financing and Intended Use of Proceeds

     

    In connection with the business combination agreement and as a condition to its closing, GH Power is pursuing a private investment in public equity financing, commonly referred to as a PIPE, to capitalize the combined company.

     

    GH Power currently expects to use the net proceeds from any PIPE financing to support commercial project deployment in North America and Europe; further engineering and scaling of its proprietary modular reactor systems; and opportunities involving industrial decarbonization, behind-the-meter power, clean hydrogen, critical materials, critical minerals, and decentralized energy.

     

    Closing Conditions and Timing

     

    GH Power currently expects the business combination to close in the fourth quarter of 2026. Closing is subject to satisfaction or waiver of applicable conditions, including:

     

    ●approval by Matinas stockholders and the requisite GH Power securityholders;
    ●Ontario court approval of the plan of arrangement;
    ●effectiveness of the Form F-4 registration statement;
    ●GHP International qualifying as a foreign private issuer at closing;
    ●completion of financing resulting in gross proceeds of at least $15.0 million; and
    ●approval to list GHP International’s common shares on the NYSE American.

     

    The transaction will require GH Power, Matinas, and GHP International to incur costs related to the business combination, SEC registration, shareholder approvals, the PIPE financing, the exchange listing, and ongoing public-company operations. The transaction also remains subject to market, financing, regulatory, execution, and post-closing trading risks. There can be no assurance that it will be completed on the anticipated terms or timetable, or at all.

     

    What the Transaction Means for GH Power Shareholders

     

    If the business combination is completed and the listing is approved, GH Power shareholders will hold common shares of a publicly traded company, which we believe will provide enhanced strategic visibility and the potential for market liquidity. Those shares will remain subject to applicable securities-law resale restrictions, any contractual lock-up restrictions, and market conditions.

     

    The definitive agreement is an important step in the transaction process, but significant work and conditions remain before closing. We will keep you informed as the transaction progresses and as additional information becomes available.

     

    Thank you for your continued support.

     

    Sincerely,

     

    Dave White

     

    Chief Executive Officer

     

    * * *

     

     
     

     

    Important Information About the Proposed Business Combination and Where to Find It

     

    This communication is being made in connection with the proposed business combination involving GH Power, Matinas, and the newly formed Ontario parent company expected to be named GH Power International, as well as related shareholder and stockholder approvals. In connection with the proposed business combination and related approvals, Matinas, GH Power, and GHP International expect to file a registration statement on Form F-4 with the U.S. Securities and Exchange Commission. The registration statement will contain a preliminary proxy statement for Matinas stockholders that will also constitute a preliminary prospectus of GHP International. As of the date of this communication, the Form F-4 has not been filed, and no definitive proxy statement/prospectus is available. After the registration statement is declared effective, Matinas will mail a definitive proxy statement/prospectus to its stockholders.

     

    INVESTORS, STOCKHOLDERS, SHAREHOLDERS, AND OTHER INTERESTED PERSONS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MATINAS, GH POWER, GHP INTERNATIONAL, THE PROPOSED BUSINESS COMBINATION, AND RELATED MATTERS. Matinas stockholders will be able to obtain free copies of the proxy statement/prospectus, when available, and other documents filed with the SEC by Matinas or GHP International by directing a request to jjabbour@MatinasBioPharma.com. These documents will also be available, without charge, on the SEC’s website at www.sec.gov.

     

    Participants in the Solicitation

     

    Matinas, GH Power, GHP International, and their respective directors, executive officers, and other members of management and employees may, under SEC rules, be deemed participants in the solicitation of proxies from Matinas stockholders in connection with the proposed business combination and related matters. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of Matinas’s directors and executive officers in the sections titled “Directors and Executive Officers” and “Executive Compensation” in Matinas’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026, which is available at https://www.sec.gov/ix?doc=/Archives/edgar/data/1582554/000149315226014132/form10-k.htm. Information regarding the persons who may be deemed participants in the solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be included in the proxy statement/prospectus and other relevant materials when they become available. These documents, once available, may be obtained free of charge from the SEC’s website at www.sec.gov or by directing a request to jjabbour@MatinasBioPharma.com.

     

    No Offer or Solicitation

     

    This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval with respect to the proposed business combination or any other transaction described herein. No securities may be offered or sold in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that jurisdiction. No offering of securities in connection with the proposed transaction will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, pursuant to an exemption from, or in a transaction not subject to, registration requirements, or pursuant to applicable prospectus exemptions under Canadian securities laws.

     

    Forward-Looking Statements

     

    This communication contains forward-looking statements within the meaning of the U.S. federal securities laws regarding the proposed business combination involving Matinas, GH Power, and GHP International. These statements include, among others, statements regarding the anticipated benefits and timing of the proposed business combination; GH Power’s assets, technology, development plans, and commercial opportunities; the PIPE financing; the expected ownership, capitalization, and listing of GHP International; satisfaction of closing conditions; access to public capital markets; commercialization and project deployment; strategic partnerships and market opportunities; financing and use of proceeds; and future financial condition, performance, and strategy. Forward-looking statements generally may be identified by words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “may,” “should,” “will,” “would,” “will continue,” “will likely result,” and similar expressions.

     

    Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to: the risk that the proposed business combination may not be completed in a timely manner or at all; failure to satisfy closing conditions, including Matinas stockholder approval, GH Power securityholder approval, Ontario court approvals, effectiveness of the Form F-4 registration statement, completion of GH Power financing resulting in gross proceeds of at least $15.0 million, GHP International qualifying as a foreign private issuer at closing, and listing of GHP International’s securities on the NYSE American; failure to realize the anticipated benefits of the proposed business combination; costs associated with the proposed business combination and becoming a public company; changes in business, market, financial, political, and regulatory conditions; risks relating to GHP International’s anticipated operations and business; the outcome of any legal proceedings that may be instituted against Matinas, GH Power, GHP International, or others following announcement of the proposed business combination; and the risk factors discussed in documents that Matinas has filed, or that Matinas and/or GHP International will file, with the SEC. Matinas, GH Power, and GHP International undertake no obligation to update any forward-looking statements except as required by applicable law.

     

     

    Get the next $MTNB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTNB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTNB
    SEC Filings

    View All

    SEC Form 425 filed by Matinas Biopharma Holdings Inc.

    425 - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

    7/16/26 5:27:14 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Matinas Biopharma Holdings Inc.

    425 - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

    7/13/26 8:08:12 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas Biopharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

    7/13/26 8:05:22 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Murphy Keith

    4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

    5/2/25 5:19:45 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Neugeboren Edward

    4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

    5/2/25 5:19:50 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Smith Robin L

    4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

    5/2/25 5:19:48 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Matinas BioPharma downgraded by Piper Sandler

    Piper Sandler downgraded Matinas BioPharma from Overweight to Neutral

    5/11/21 8:00:37 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma

    Following the transaction, the new public company will focus its efforts on the continued development and scale-up of GH Power’s technology platform, expanding project development activities in North America and Europe, and advancing commercial deployment opportunities across energy, industrial, and critical materials applications GH Power Inc. ("GH Power") today announced that it has entered into a definitive Business Combination Agreement (the "Business Combination Agreement") with Matinas BioPharma Holdings, Inc. (NYSE:MTNB) ("Matinas") for a proposed business combination that is expected to result in a NYSE-listed, publicly-traded critical minerals and clean energy company focused on

    7/13/26 3:45:00 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

    Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization  Business Combination expected to provide public market platform to accelerate commercialization, project development and strategic growth across North America and Europe Definitive agreement provides for the sale of Matinas BioPharma Nanotechnologies, Inc., including MAT2203 and the LNC technology platform, to Azurity Pharmaceuticals for $4.0 million upfront, up to an additional $17.5 million in potential milestones and future mid-single-digit royalties BEDMINSTER, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Hol

    7/13/26 8:00:00 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

    BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:MTNB) announced today that on June 24, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders’ equity of $3.02 million and ha

    6/26/26 5:15:00 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Leadership Updates

    Live Leadership Updates

    View All

    Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

    BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

    3/11/25 7:00:00 AM ET
    $GRCE
    $MTNB
    $ONVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

    BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a certain group of investors (the "Investors"), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the "Preferred Stock") and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company. The Investors purchased 1,650 shares of

    2/13/25 5:00:00 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

    BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D'An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, techn

    2/7/25 7:30:00 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Financials

    Live finance-specific insights

    View All

    Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

    BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available o

    8/7/24 7:00:00 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

    BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will be available on the IR Ca

    5/2/24 7:00:00 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

    Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improved safety of LNC-docetaxel over IV-docetaxel, with similar efficacy, supports the future use of the LNC platform in inflammation and oncology Conference call begins at 4:30 p.m. Eastern time today

    3/27/24 4:05:00 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTNB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Matinas Biopharma Holdings Inc.

    SC 13G - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

    10/25/24 9:15:12 AM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Matinas Biopharma Holdings Inc. (Amendment)

    SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

    2/14/22 4:43:03 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

    2/16/21 5:01:52 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care